DENVER, Colo., Aug 29, 2025 (247marketnews.com)- A flurry of pivotal developments across diagnostics, biotech, aerospace, pet retail, and mobile gaming set the tone for today’s markets.
NeoGenomics (NASDAQ:NEO) secured a major legal victory—winning summary judgment in its patent battle with Natera (NASDAQ:NTRA). The court ruled Natera’s patents invalid for claiming ineligible subject matter, clearing the way for NeoGenomics to freely commercialize RaDaR ST, its molecular residual disease (MRD) assay in the U.S.
CEO Tony Zook said, “We are pleased with the Court’s decision… committed to providing … options for their MRD testing.”
NEO remains free to make, use, sell, and promote its RaDaR ST assay and is moving forward with biopharma commercialization and CMS reimbursement lodging through MolDX.
Pasithea Therapeutics (NASDAQ:KTTA) is advancing at pace. The company completed enrollment and initial dosing of Cohort 1 (three patients) in its Phase 1/1b PAS-004 trial for NF1 (neurofibromatosis type 1) patients, a novel macrocyclic MEK inhibitor.
Initial interim data is expected in Q1 2026, signaling potential momentum for this early-stage biotech.
LIXTE Biotechnology (NASDAQ:LIXT) is ascending ahead of its presentation at a global conference spotlighting a groundbreaking approach: “activating oncogenic signaling to kill cancer cells.” The peer-reviewed journal Trends in Cancer underscored LIXTE’s leadership, noting its PP2A inhibitor, LB‑100, may “drive tumor cells into lethal hyperactivation” while boosting immune visibility through neoantigen formation.
Nukkleus (NASDAQ:NUKK) announced a strategic joint venture with Israel-based Mandragola focused on modernizing civil and defense aviation infrastructure across the Baltics and Israel. Initiatives include NATO-compliant logistics hubs, MRO services, and early-stage tech investment.
CEO Menny Shalom highlighted the move as part of “building a platform capable of servicing both commercial and defense applications,” while Mandragola’s CEO said it blends “aviation industry relationships, technology ecosystem connections, and capital markets expertise.”
Petco (NASDAQ:WOOF) released a steady Q2:
- Net sales: $1.5B (-2.3% YoY)
- Comparable sales: -1.4%
- Gross margin: expanded ~120 basis points to 39.3%
- Operating income: improved by $40.6M to $43M
- GAAP net income: positive at $14M
- Adjusted EBITDA: rose $30.3M to $113.9M
CEO Joel Anderson noted the company “raised our earnings outlook for the full year,” pointing to a “solid foundation” from H1.
Movano Health (NASDAQ:MOVE) got a lifeline from Nasdaq’s Hearings Panel, granting it extra time to regain listing compliance. The company has until Sept 30 to file its Q1 & Q2 2025 reports and until Oct 30 to elevate its share price above $1, with a reverse split under consideration.
Gamehaus Holdings (NASDAQ:GMHS) authorized a $5M share repurchase program active until August 2026. The buyback will be funded through existing cash and open-market or private transactions. Chairman Feng Xie said it’s a “balanced approach to capital allocation,” signaling that “current share price does not fully reflect the strength of our fundamentals.”
It seems like we’ve covered Opendoor (NASDAQ:OPEN) and Sound Group (NASDAQ:SOGP) throughout the trading week.
Opendoor continues attracting interest as a transformative iBuying platform. Reddit traders and analysts liken its model to a 1997-style Amazon analogue, noting the company’s operational resilience despite macro headwinds and potential upside from declining interest rates.
Sound Group has held investor attention thanks to a recently declared special cash dividend ($1.00 per ADS), signaling operational strength in its AI-powered audio and entertainment platform.
Professional Diversity Network (NASDAQ:IPDN) is emerging from the shadows with its Q1 2025 results showing a reduced net loss, improved cash flow, and expanded AI investment, specifically a $1.3M stake in AI Geometric to enhance its TalentAlly recruitment platform. Meanwhile, StockNews.com initiated coverage with a “sell” rating, keeping tab on downbeat sentiment.
Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information
The post Morning Market Recap: Precision Medicine Clears the Path, A&D Soars, and Gaming Gets a Buyback Boost appeared first on 24/7 MarketNews.
